Anonymous
Guest
Anonymous
Guest
All of you stated the truth. Pediatric vaccines bring in a steady stream of revenue for Merck. That is always our strength. May be a hassle to the PCP but it is another office call, patient retention, loss leader or whatever you want to call it. Then we apply the pill model to all those adult vaccines to expand the market, create the needs, etc. I have seen only one PCP that got excited about all these and his worry was how to get them and get reimbursed without losing money.
That's why this f'en division is going down. Leadership/management trying to sell vaccines via the tablet model. Duh!